These results advocate that enhanced endogenous TGF‐β1 and autocrine TGF‐β signalling in T2DM contributes to the VEGFA resistance and monocyte dysfunction in patients with T2DM. This evidence concerns the gene VEGFA and type 2 diabetes mellitus.